Treatment of autoimmune arthritis by oral administration of type I or type III collagen

• US 5,733,547 A
• Filed: 06/02/1995
• Issued: 03/31/1998
• Est. Priority Date: 06/24/1987
• Status: Expired due to Fees

• Current Assignee: Autoimmune, Inc.
• Original Assignee: Autoimmune, Inc.
• Inventors: Weiner, Howard L., Hafler, David A.
• Primary Examiner(s): Achutamurthy, Ponnathapura
• Application Number:
  US08/461,586
• Time in Patent Office: 1,033 Days
• Field of Search: 424/184.1, 424/185.1, 514/2, 514/21, 514/825, 530/350, 530/354, 530/356, 530/387.1
• US Class Current: 424/184.1
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: C07K 14/4713 Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Claims

1. A method for treating rheumatoid arthritis in a subject, comprising suppressing a T-cell mediated autoimmune response associated with said arthritis by orally administering to said subject a composition comprising a therapeutically effective amount of type I or type III collagen.

2. The method of claim 1, wherein the therapeutically effective amount is from about 10 μ

g to about 100 mg per day.

3. The method of claim 1, wherein the therapeutically effective amount is from about 100 μ

g to about 30 mg per day.

4. The method of claim 1 comprising administering type I collagen.

5. The method of claim 1 comprising administering type III collagen.

6. The method of claim 4 wherein said collagen is solubilized in a medium that is pharmaceutically acceptable for oral administration.

7. The method of claim 5 wherein said collagen is solubilized in a medium that is pharmacentically acceptable for oral administration.

8. A method for suppressing T-cell mediated autoimmune response associated with rheumatoid arthritis in a subject, comprising orally administering to said subject an amount of type I or type III collagen effective to suppress said autoimmune response.

9. The method of claim 8, wherein the therapeutically effective amount is from about 10 μ

g to about 100 mg per day.

10. The method of claim 9, wherein the therapeutically effective amount is from about 100 μ

g to about 30 mg per day.

11. The method of claim 8 comprising administering type I collagen.

12. The method of claim 8 comprising administering type III collagen.

13. The method of claim 11 wherein said collagen is solubilized in a medium that is pharmaceutically acceptable for oral administration.

14. The method of claim 12 wherein said collagen is solubilized in a medium that is pharmaceutically acceptable for oral administration.